人工智能 (AI) 相关的联盟和授权合约 (2016～2024年)

在本报告中，我们分析了人工智慧 (AI) 相关联盟和授权协议的最新趋势（2016-2024 年），包括交易总数的趋势、财务方面的趋势（支付条款），此外调查主要公司（共25家公司）的交易形成趋势、合约条件的趋势、技术的详细趋势等，并彙整近年来主要合作交易的详细资讯。

目录

摘要整理

第1章 简介

第2章 人工智能相关的交易形成的倾向

• 简介
• 人工智能相关的交易的长期趋势
• 人工智能相关最活跃的交易业者
• 人工智能相关的交易:各交易类型
• 人工智能相关的交易:各治疗领域
• 人工智能相关的交易:各业界
• 人工智能相关的交易:交易条件
  • 人工智能相关的交易:交易总额
  • 人工智能相关的交易:预付款金
  • 人工智能相关的交易:阶段性付款
  • 人工智能相关的交易:权利金费率

第3章 人工智能相关的主要交易

• 简介
• 人工智能相关的主要交易:各金额

第4章 人工智能相关最活跃的交易企业

• 简介
• 人工智能相关的最活跃的交易企业
• 人工智能相关的最活跃的交易企业的简介

第5章 人工智能相关的契约缔结一览

• 简介
• 人工智能相关的契约缔结一览

第6章 人工智能相关的交易:各技术种类

• 交易一览
• 交易一览:人工智能相关，各企业 (ABC顺序)
• 交易一览:人工智能相关，各交易类型
• 交易一览:人工智能相关，各治疗领域
• 交易的种类定义
• 关于Biopharma Research Ltd
• 目前联盟
• 目前契约
• Current Partnering出版的最近报告标题

Artificial Intelligence (AI) Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the artificial intelligence deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of artificial intelligence deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter artificial intelligence deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 965 artificial intelligence deals announced since 2016 including financial terms where available including links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of artificial intelligence dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in artificial intelligence dealmaking since 2016.

Chapter 3 provides an overview of the leading artificial intelligence deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in artificial intelligence dealmaking with a brief summary followed by a comprehensive listing of artificial intelligence deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of artificial intelligence deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan 2016. The chapter is organized by specific artificial intelligence technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in artificial intelligence deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Artificial Intelligence (AI) Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse artificial intelligence collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Artificial Intelligence (AI) Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of artificial intelligence trends and structure of deals entered into by leading biopharma companies worldwide.

Artificial Intelligence (AI) Collaboration and Licensing Deals includes:

• Trends in artificial intelligence dealmaking in the biopharma industry
• Directory of artificial intelligence deal records covering pharmaceutical and biotechnology
• The leading artificial intelligence deals by value
• Most active artificial intelligence licensing dealmakers
• Artificial Intelligence (AI) Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in artificial intelligence dealmaking

• 2.1. Introduction
• 2.2. Artificial intelligence deals over the years
• 2.3. Most active artificial intelligence dealmakers
• 2.4. Artificial intelligence deals by deal type
• 2.5. Artificial intelligence deals by therapy area
• 2.6. Artificial intelligence deals by industry sector
• 2.7. Deal terms for artificial intelligence deals
  • 2.7.1 Artificial intelligence deals headline values
  • 2.7.2 Artificial intelligence deal upfront payments
  • 2.7.3 Artificial intelligence deal milestone payments
  • 2.7.4 Artificial intelligence royalty rates

Chapter 3 - Leading artificial intelligence deals

• 3.1. Introduction
• 3.2. Top artificial intelligence deals by value

Chapter 4 - Most active artificial intelligence dealmakers

• 4.1. Introduction
• 4.2. Most active artificial intelligence dealmakers
• 4.3. Most active artificial intelligence deals company profiles

Chapter 5 - Artificial intelligence contracts dealmaking directory

• 5.1. Introduction
• 5.2. Artificial intelligence contracts dealmaking directory

Chapter 6 - Artificial intelligence dealmaking by technology type

• Deal directory
• Deal directory - Artificial intelligence deals by company A-Z
• Deal directory - Artificial intelligence deals by deal type
• Deal directory - Artificial intelligence deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Artificial intelligence deals since 2016
• Figure 2: Active artificial intelligence dealmaking activity - 2016 - 2024
• Figure 3: Artificial intelligence deals by deal type since 2016
• Figure 4: Artificial intelligence deals by therapy area since 2016
• Figure 5: Artificial intelligence deals by industry sector since 2016
• Figure 6: Artificial intelligence deals with a headline value
• Figure 7: Artificial intelligence deals with an upfront value
• Figure 8: Artificial intelligence deals with a milestone value
• Figure 9: Artificial intelligence deals with a royalty rate value
• Figure 10: Top artificial intelligence deals by value since 2016
• Figure 11: Most active artificial intelligence dealmakers 2016 - 2024
• Figure 12: Artificial intelligence deals by technology type since 2016